Literature DB >> 7882309

Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias.

J A Pietenpol1, S K Bohlander, Y Sato, N Papadopoulos, B Liu, C Friedman, B J Trask, J M Roberts, K W Kinzler, J D Rowley.   

Abstract

The p27Kip1 (p27) gene encodes an inducible inhibitor of cyclin-dependent kinase activity. Using a murine p27 cDNA as probe, we obtained a human cDNA clone and subsequently used it to isolate a genomic clone of this gene. The coding region of the human p27 gene was contained in two exons. Both the amino acid sequence and intron-exon organization of p27 were similar to those previously found for the related cyclin-dependent kinase inhibitor p21Waf1 (p21). The p27 gene was localized to chromosome band 12p13 by a combination of somatic cell hybrid and fluorescence in situ hybridization analyses. The p27 gene product is thought to control the leukocyte cell cycle and the 12p13 chromosomal band is known to be deleted in leukemias, suggesting that the p27 gene may act as a tumor suppressor gene in leukemias. Although p27 was found to reside in the minimal region of chromosomal loss in hematological malignancies, no mutations of p27 were observed in leukemia samples. Haploinsufficiency of p27 may confer a growth advantage to leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882309

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  The p27/Kip1 locus shows no loss of heterozygosity in human pituitary adenomas.

Authors:  J C Wilson; J J Zhu; P M Black
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  p27KIP1 deletions in childhood acute lymphoblastic leukemia.

Authors:  H Komuro; M B Valentine; J E Rubnitz; M Saito; S C Raimondi; A J Carroll; T Yi; C J Sherr; A T Look
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

3.  Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.

Authors:  L Jin; X Qian; E Kulig; N Sanno; B W Scheithauer; K Kovacs; W F Young; R V Lloyd
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

4.  Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

Authors:  T Tokino; T Urano; T Furuhata; M Matsushima; T Miyatsu; S Sasaki; Y Nakamura
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 5.  New insights into the tumor suppression function of P27(kip1)

Authors:  B E Clurman; P Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 6.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression.

Authors:  M L Fero; E Randel; K E Gurley; J M Roberts; C J Kemp
Journal:  Nature       Date:  1998-11-12       Impact factor: 49.962

8.  Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior?

Authors:  Latife Doganay; Semsi Altaner; Selcuk Bilgi; Esat Kaya; Galip Ekuklu; Kemal Kutlu
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

9.  Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer.

Authors:  H Kawana; J Tamaru; T Tanaka; A Hirai; Y Saito; M Kitagawa; A Mikata; K Harigaya; T Kuriyama
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability.

Authors:  Shannon R Payne; Shulin Zhang; Karen Tsuchiya; Russell Moser; Kay E Gurley; Gary Longton; Johan deBoer; Christopher J Kemp
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.